Send the following on WhatsApp
Continue to Chat信達生物在2022年美國血液病學年會(ASH)上公佈IBI188(抗CD47單抗)治療一線中高危骨髓增生異常綜合征臨床數據更新 https://geneonline.news/%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e5%9c%a82022%e5%b9%b4%e7%be%8e%e5%9c%8b%e8%a1%80%e6%b6%b2%e7%97%85%e5%ad%b8%e5%b9%b4%e6%9c%83%ef%bc%88ash%ef%bc%89%e4%b8%8a%e5%85%ac%e4%bd%88ibi188%ef%bc%88/